About Us
CuraGen AI exists to design disease-modifying small molecules that restore lives devastated by Endocinological disorders, Alzheimer’s and hard-to-treat cancers. Our mission is to end PCOS, neurodegeneration and lethal malignancies by fusing AI, quantum computing and deep biology—delivering cures at digital speed.
Our Story
CuraGen AI was born from a simple idea: drug discovery should move at the speed of insight. After two decades advancing oncology and data science, our founder created CureRx™, a proprietary modular platform that fuses generative AI with physics-based rigor—including docking, molecular dynamics, and quantum-assisted FEP—to design and prioritize novel small molecules with true developability in mind. We integrate state-of-the-art structure prediction, scaffold generation, and ADMET optimization into rapid Design→Make→Test→Learn loops, turning weeks into days and concepts into assay-ready candidates. Our focus spans endocrinological disorders, oncology, and Alzheimer’s disease—areas where precision and time matter most. With a trusted network of CRO partners and clear biomarker-anchored go/no-go gates, we aim to de-risk earlier, file strong IP, and deliver first-in-class therapies faster and more cost-effectively. If you’re building the future of medicines, we’d love to build it with you.
Sharad Agarwal
Sharad Agarwal is a life sciences and AI leader with 20+ years across oncology, data science, and clinical development. As Founder of CuraGen AI Labs, he builds an AI-native discovery platform that unites generative models with docking, MD, and quantum-assisted FEP to prioritize patent-ready chemotypes and compress AI→assay cycles from years to weeks. He has led global teams in the U.S. and China, delivered FDA/EMA submissions, and led regulatory submission and approval for lung-cancer therapies (e.g., Rybrevant®). He holds a medical degree (MBBS) from India and advises biopharma and start-ups on AI adoption, biomarkers, and IND-ready evidence in endocrinology, oncology, and Alzheimer’s disease.
Amrit Bhangoo
Dr. Bhangoo is a pediatric endocrinology leader with 20+ years’ clinical experience. He serves as Associate Professor of Pediatrics at UC Irvine and Section Chief of Pediatric Endocrinology at Children’s Hospital of Orange County. His clinical and research interests span PCOS, premature adrenarche, glucocorticoid resistance, Noonan syndrome, achondroplasia, neonatal hypoglycemia, and the endocrine effects of bone marrow transplantation. He has authored 50+ peer-reviewed publications, written five book chapters, and edited a medical textbook on Noonan syndrome. A frequent reviewer and editorial board member across multiple journals, he also serves on the board of the Human Growth Foundation.
Rory Popert
Rory Popert is a life sciences and technology leader with 15+ years’ experience spanning academia, industry, and start-ups. He has led national-scale precision medicine and genomics programmes, built AI-enabled data platforms, and advised C-suite leaders on strategy, innovation, and commercialisation. As Co-Founder of Unison, Rory develops solutions for complex data federation and interoperability in biopharma and research. He also serves on advisory boards for multiple deep-tech and biotech ventures, including CuraGenAI.
